Jinnouchi, Hideaki http://orcid.org/0000-0002-7391-7966
Yoshida, Akira http://orcid.org/0000-0002-5463-6114
Taniguchi, Mariko
Yamauchi, Eisaku
Kurosawa, Daisuke
Yachiku, Kenji
Minoura, Itsushi http://orcid.org/0000-0001-7822-1004
Kadowaki, Takashi
Yamauchi, Toshimasa http://orcid.org/0000-0003-4827-6404
Aihara, Masakazu
Kubota, Naoto http://orcid.org/0000-0002-3336-2767
Sekimizu, Koshin http://orcid.org/0000-0003-0427-9291
Funding for this research was provided by:
Japan Agency for Medical Research and Development (21le0110022h0001)
Article History
Received: 22 March 2024
Accepted: 25 April 2024
First Online: 16 May 2024
Declarations
:
: Provigate, Inc. sponsored the joint research project. Hideaki Jinnouchi holds stocks in Provigate, Inc. Koshin Sekimizu is the founder of Provigate, Inc. Daisuke Kurosawa, Kenji Yachiku, and Itsushi Minoura are employed by Provigate, Inc. Takashi Kadowaki is an Editorial Board member of <i>Diabetes Therapy</i>. Takashi Kadowaki was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. All other authors declare that they have no relationships or activities to declare that might introduce bias, or be perceived as introducing bias, in their work.
: The Fujita Health University Certified Review Board (CRB4180003) approved the study protocol and the informed consent form. We conducted this study was conducted in accordance with the Japanese Clinical Trials Act (Act No. 16 of April 14, 2017), the ethical principles of the Helsinki Declaration of 1964, its later amendments, and all applicable laws and guidelines in Japan. The study was registered at the Japan Registry of Clinical Trials (, jRCTs042220048).